Mark Belkin, MD
Internal Medicine · Chicago, ILNPI 1023499498
Payments from drug & device makers
Across 187 payments — averaging $333.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$27K
- Abbott$14K
- United Therapeutics Corporation$8K
- Bayer$8K
- Medtronic$2K
- AOP Health US, LLC$1K
- plus $3K from 26 others
What the payments were for
- Consulting fees$7,35026%
- Grants$11,19840%
- Travel & lodging$4682%
- Food & beverage$8,48130%
- Education$4242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $26,645 |
| Abbott | 63 | $14,168 |
| United Therapeutics Corporation | 2 | $8,180 |
| Bayer | 8 | $7,629 |
| Medtronic(2 entities) | 6 | $1,556 |
| AOP Health US, LLC | 2 | $1,082 |
| Cvrx, Inc. | 6 | $639 |
| Abiomed | 8 | $472 |
| Endotronix, Inc. | 3 | $294 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $245 |
| Novartis | 6 | $188 |
| Pfizer | 10 | $171 |
| Boston Scientific | 2 | $145 |
| Amgen | 8 | $140 |
| Paragonix Technologies, Inc. | 2 | $138 |
| Lantheus Medical Imaging, Inc. | 7 | $111 |
| Johnson & Johnson | 7 | $105 |
| Daiichi Sankyo Inc. | 3 | $80 |
| Regeneron Healthcare Solutions, Inc. | 5 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Bridgebio Pharma, Inc. | 1 | $45 |
| Heartflow, Inc. | 1 | $43 |
| Boehringer Ingelheim | 2 | $36 |
| ZOLL Circulation Inc | 1 | $35 |
| Daxor Corporation | 1 | $34 |
| Merck | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Medicomp Inc | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Procyrion, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$6,900
- Rapiblyk$2,164
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,108
- Adempas$600
- Barostim Neo System$566
- HeartMate 3 Left Ventricular Assist Device$328
- HeartMate 3 Left Ventricular Dev$321
- EnSite Precision Cardiac Mapping System$141
- Impella$139
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$138
- HeartWare HVAD$137
- Watchman$121
- CARDIOMEMS$111
- SelectSecure$110
- LifeVest$102
How this compares
$62,454 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 64 | $879,982 |
| Tyvaso DpiTreprostinil | 19 | $449,055 |
| OpsumitMacitentan | 33 | $425,860 |
| EntrestoSacubitril/Valsartan | 51 | $63,613 |
| JardianceEmpagliflozin | 36 | $56,149 |
| Ambrisentan | 11 | $37,132 |
| FarxigaDapagliflozin Propanediol | 22 | $28,260 |
| OzempicSemaglutide | 19 | $19,932 |
| Valsartan | 18 | $1,137 |
| Spironolactone | 124 | $1,123 |
| Metoprolol Succinate | 41 | $474 |
| Torsemide | 11 | $239 |
| Atorvastatin Calcium | 12 | $191 |
| Rosuvastatin Calcium | 12 | $162 |
| Carvedilol | 22 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $7,629 | $879,98264 claims |
| NovartisEntresto | $188 | $63,61351 claims |
| Boehringer IngelheimJardiance | $36 | $56,14936 claims |
| AstraZenecaFarxiga | $26,645 | $28,26022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.